Oncopeptides (Sweden) Market Value
| ONCO Stock | SEK 1.51 0.01 0.67% |
| Symbol | Oncopeptides |
Oncopeptides 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oncopeptides' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oncopeptides.
| 09/28/2024 |
| 11/27/2024 |
If you would invest 0.00 in Oncopeptides on September 28, 2024 and sell it all today you would earn a total of 0.00 from holding Oncopeptides AB or generate 0.0% return on investment in Oncopeptides over 60 days. Oncopeptides is related to or competes with Hansa Biopharma, BioArctic, Sinch AB, and Cantargia. Oncopeptides AB , a pharmaceutical company, develops drugs for the treatment of cancer More
Oncopeptides Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oncopeptides' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oncopeptides AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 34.67 | |||
| Value At Risk | (3.69) | |||
| Potential Upside | 3.83 |
Oncopeptides Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncopeptides' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oncopeptides' standard deviation. In reality, there are many statistical measures that can use Oncopeptides historical prices to predict the future Oncopeptides' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.53) | |||
| Total Risk Alpha | (1.08) | |||
| Treynor Ratio | (1.33) |
Oncopeptides AB Backtested Returns
Oncopeptides AB maintains Sharpe Ratio (i.e., Efficiency) of -0.13, which implies the firm had a -0.13% return per unit of risk over the last 3 months. Oncopeptides AB exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Oncopeptides' Risk Adjusted Performance of (0.09), variance of 14.22, and Coefficient Of Variation of (799.94) to confirm the risk estimate we provide. The company holds a Beta of 0.36, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Oncopeptides' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oncopeptides is expected to be smaller as well. At this point, Oncopeptides AB has a negative expected return of -0.48%. Please make sure to check Oncopeptides' coefficient of variation, jensen alpha, treynor ratio, as well as the relationship between the standard deviation and total risk alpha , to decide if Oncopeptides AB performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.60 |
Good predictability
Oncopeptides AB has good predictability. Overlapping area represents the amount of predictability between Oncopeptides time series from 28th of September 2024 to 28th of October 2024 and 28th of October 2024 to 27th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oncopeptides AB price movement. The serial correlation of 0.6 indicates that roughly 60.0% of current Oncopeptides price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.6 | |
| Spearman Rank Test | 0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Oncopeptides AB lagged returns against current returns
Autocorrelation, which is Oncopeptides stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Oncopeptides' stock expected returns. We can calculate the autocorrelation of Oncopeptides returns to help us make a trade decision. For example, suppose you find that Oncopeptides has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Oncopeptides regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Oncopeptides stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Oncopeptides stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Oncopeptides stock over time.
Current vs Lagged Prices |
| Timeline |
Oncopeptides Lagged Returns
When evaluating Oncopeptides' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Oncopeptides stock have on its future price. Oncopeptides autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Oncopeptides autocorrelation shows the relationship between Oncopeptides stock current value and its past values and can show if there is a momentum factor associated with investing in Oncopeptides AB.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Oncopeptides Stock Analysis
When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.